Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy

SIMPLE SUMMARY: Osimertinib has become the standard of care for the first-line treatment of EGFR-mutant NSCLC patients. The aim of this current translational research study was to assess the clinical relevance of liquid biopsy in 47 patients receiving osimertinib. Effects on circulating tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallergi, Galatea, Kontopodis, Emmanouil, Ntzifa, Aliki, Jordana-Ariza, Núria, Karachaliou, Niki, Pantazaka, Evangelia, Charalambous, Haris A., Psyrri, Amanda, Tsaroucha, Emily, Boukovinas, Ioannis, Koumarianou, Anna, Hatzidaki, Dora, Lianidou, Evi, Georgoulias, Vassilis, Rosell, Rafael, Kotsakis, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946716/
https://www.ncbi.nlm.nih.gov/pubmed/35326725
http://dx.doi.org/10.3390/cancers14061574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946716/
https://www.ncbi.nlm.nih.gov/pubmed/35326725
http://dx.doi.org/10.3390/cancers14061574

Ejemplares similares